This is a preview of subscription content, log in via an institution to check access.
References
C. Confavreux, G. Aimard, and M. Devic, “Course and prognosis of multiple sclerosis assessed by computerized data processing of 349 patients,” Brain, 103, 281–300 (1980).
“European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicenter randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis,” Lancet, 352, 1491–1497 (1998).
G. Ebers, A. Traboulsee, D. Langdon, et al., “Final results from the interferon β-1b 16 year long-term follow-up study,” Poster presented at ECTRIMS, Madrid (2006), p. 666.
IFNB Multiple Sclerosis Study Group, “Interferon β-1b is effective in relapsing-remitting multiple sclerosis. 1. Clinical results of multicenter, randomised, double-blind, placebo-controlled trial,” Neurology, 43, 655–661 (1993).
L. D. Jacobs, D. L. Cookfair, R. A. Rudick, et al., “Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis,” Ann. Neurol., 39, 285–294 (1996).
L. D. Jacobs, R. W. Beck, J. H. Simon, et al., “Intramuscular interferon β-1a therapy initiated during a first demyelinating event in multiple sclerosis CHAMPS Study Group,” New Eng. J. Med., 343, 898–904 (2000).
R. P. Kinkel, C. Kollman, P. O’Connor, et al., “CHAMPIONS Study Group. IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event,” Neurology, 66, 678–684 (2006).
J. Kuhle, M. Hardmeier, M. D. Hooghe, et al., “On behalf of the EUSPMS long-term follow-up of European Study of interferon β-1b (EUSPMS) in secondary progressive MS,” Mult. Scler., 9, Supplement 1, 143 (2003).
L. Kappos, A. Traboulsee, C. Constaninescu, et al., “Long-term subcutaneous interferon (β-1a therapy in patients with relapsing-remitting MS,” Neurology, 67, 944–953 (2006).
B. Runmarker and O. Andersen, “Prognostic factors in multiple sclerosis incidence cohort with twenty-five years of follow-up,” Brain, 116, No. 1, 117–134 (1993).
R. A. Rudick, G. R. Cutter, M. Baier, et al., “Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients,” Mult. Scler., 11, 626–634 (2005).
“PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing- remitting multiple sclerosis,” Lancet, 352, 1498–1504 (1998).
“PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group PRISMS-4: Long-term efficacy of interferon β-1a in relapsing MS,” Neurology, 56, 1628–1636 (2001).
“The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon β-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial,” Neurology, 45, 1277–1285 (1995).
B. G. Weinshenker, B. Bass, G. P. Rice, et al., “The natural history of multiple sclerosis: geographically based study. I. Clinical course and disability,” Brain, 112, No. 1, 133–146 (1989).
B. G. Weinshenker, “The natural history of multiple sclerosis,” Neurol. Clin., 13, 119–146 (1995).
Author information
Authors and Affiliations
Additional information
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 108, No. 4, pp. 24–26, April, 2008.
Rights and permissions
About this article
Cite this article
Demina, T.L., Khachanova, N.V., Davydovskaya, M.V. et al. Efficacy and Safety of Prolonged Immunomodulatory Treatment with Interferon Beta. Neurosci Behav Physi 39, 497–499 (2009). https://doi.org/10.1007/s11055-009-9151-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-009-9151-5